Common Equity (Quarterly)

Common Equity: The sum of all common equity items.

ImmunityBio, Inc. (IBRX) had Common Equity of $-499.57M for the most recently reported fiscal quarter, ending 2025-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-12-31

Income Statement Financials
Revenue	$38.28M
Net Income	$-61.94M
Cost of Goods Sold	$0.38M
Gross Profit	$37.90M
Operating Expenses	$102.97M
Operating Income	$-64.68M
Non-Operating Income/Expense	$2.59M
Pre-Tax Income	$-62.09M
Normalized Pre-Tax Income	$-62.09M
Income after Taxes	$-61.96M
Income from Continuous Operations	$-61.96M
Consolidated Net Income/Loss	$-61.96M
Normalized Income after Taxes	$-61.96M
EBIT	$-64.68M
EBITDA	$-60.82M
Weighted-Average Shares Outstanding (Basic)	919.86M
Weighted-Average Shares Outstanding (Diluted)	919.86M
Earnings per Share (EPS) (Basic)	$-0.06
Earnings per Share (EPS) (Diluted)	$-0.06
Balance Sheet Financials
Current Assets	$314.88M
Property, Plant, and Equipment	$114.26M
Long-Term Assets	$187.02M
Total Assets	$501.90M
Current Liabilities	$61.75M
Long-Term Debt	$477.09M
Long-Term Liabilities	$939.72M
Total Liabilities	$1.00B
Common Equity	$-499.57M
Tangible Shareholders Equity	$-513.53M
Shareholders Equity	$-499.57M
Common Shares Outstanding	1.01B
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-304.94M
Cash Flow from Investing Activities	$-149.80M
Cash Flow from Financial Activities	$400.24M
Beginning Cash	$143.91M
End Cash	$89.43M
Increase/Decrease in Cash	$-54.48M
Stock-Based Compensation	$36.81M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.10
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-21.22
Debt to Equity Ratio	-0.95
Gross Margin	99.00%
Operating Margin	-168.95%
EBIT Margin	-168.95%
EBITDA Margin	--
Pre-Tax Profit Margin	-162.19%
Profit Margin	-161.80%
Free Cash Flow	$-308.78M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.08
Inventory Turnover	0.42
Receiveable Turnover	0.90
Days Sales in Receivables	100.08
Return on Equity	12.40%
Return on Tangible Equity	12.07%
Return on Assets	-12.34%
Return on Investments	275.60%
Book Value Per Share	$-0.49
Free Cash Flow per Share	$-0.34
Operating Cash Flow per Share	$-0.33

Data from Zacks Investment Research, Inc.